Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis.

Front Immunol · 2026 · PMC13044012 · PMID 41939914

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The point estimate for nivolumab was also above 1.0, suggesting a potential increase in risk, but it did not reach statistical significance in our analysis.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.